In a report published Thursday, Bank of America analyst Scott D. Craig downgraded the rating on Emulex (NYSE: ELX) from Buy to Underperform ... have a hard time finding reasons to buy/own the stock, at least near-term.” Emulex closed …
ELX-02 is entering Phase 2 clinical development for Cystic Fibrosis ... and the quotation of the Company's common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company's …
Up Last 7 Days N/A N/A N/A N/A Up Last 30 Days N/A N/A N/A N/A Down Last 30 Days N/A N/A N/A N/A Down Last 90 Days N/A N/A N/A N/A
Arena Pharmaceuticals (ARNA): The pharmaceutical stock is now Hold from Buy at Hapoalim Securities. Emulex (ELX): ELX is downgraded to Hold from Buy at Jefferies. Buckeye Partners (BPL): BPL gets lowered to Hold from Buy with …
ELX-02 is entering Phase 2 clinical development for Cystic Fibrosis ... and the quotation of the Company's common …
WBOC15d
N/A Shares held by all insider and 5% owners N/A % of shares held by institutional & mutual fund owners
The Director now holds 6,366,246 shares. Shares is the leading weekly publication for high net worth private investors and stock market professionals and as such is read weekly by thousands of private investors, analysts, fund managers, …
ELX-02 is entering Phase 2 clinical development for Cystic Fibrosis ... and the quotation of the Company's common …
KHQ15d